Jun 08, 2016 7:00am EDT Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
Mar 31, 2016 7:05am EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update
Mar 07, 2016 7:05am EST Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
Feb 10, 2016 8:05am EST Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Feb 08, 2016 7:05am EST Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B
Feb 01, 2016 7:35am EST Matinas BioPharma Receives FDA Clearance to Initiate Phase 1 Clinical Study of MAT2501 for the Treatment of Non-Tuberculous Mycobacterium Infections
Jan 04, 2016 7:05am EST Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
Dec 17, 2015 7:05am EST Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
